News
14hon MSN
Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 ...
The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...
Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in ...
Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...
His appointment as an observer on the board follows the removal on Friday of current CEO Lars Fruergaard Jorgensen by Novo ...
Novo Nordisk is offering self-paying U.S. patients who are new to its weight-loss drug Wegovy their first month of medicine ...
"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...
12h
Zacks.com on MSNNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...
As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results